FORM PTO-		PARTMENT OF COMMERCE F AND TRADEMARK OFFICE		ATTY. DOCKET NO.		SERIAL NO.				
	PATENT			U013913-4		10/	10/099858			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT					
				Bonnie M. Davis						
Vise several sheets if necessary)			FI	LING DATE		GROUP				
				March 14, 2002		1617				
TO THE PERSON		U.S. P	ATENT DO	CUMENT	rs					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE		NAME		FILING DATE IF APPROPRIATE			
	AA									
	AB									
	AC									
	AD									
	AE									
	AF									
	AG									
	AH									
	, AI									
	ΑJ									
	AK									
		FOREIGN	PATENT D	OCUME	NTS					
72-61	17-7-7	DOCUMENT		- 6			TRANSLATION			
		NUMBER	DAT	E	COUNTRY		YES	NO		
	AL					Х.				
	AM									
	AN					100				
	AO									
	AP									
	OT	HER ART (Includin	ng Author, Ti	itle, Date,	Pertinent Dates, Etc.)				
	AR	Business Week January 28, 2008: article "Do Cholesterol Drugs do Any Good"								
	AS	Australian Adverse Drug Reactions Bulletin Vol 17 August 1998								
	AT	Wolzin et al "Decreased Prevalence of Alzheimer Disease with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors								
EXAMINER	/Renee Claytor	/		DATEC	CONSIDERED 1	2/17/200	8			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

		PARTMENT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO.				
	PATENT	F AND TRADEMARK OFFICE		U013913-4		10/099858				
INFORMATION DISCLOSURE				APPLICANT						
STATEMENT BY APPLICANT				Bonnie M. Davis						
	(Use several sl	heets if necessary)		FI	FILING DATE			GROUP		
				M	arch 14,2003		1617			
		U.S. I	PATENT DO	CUMEN	rs					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER DATE		NAME		FILING DATE IF APPROPRIATE				
	AA									
	AB									
	AC									
	AD	l. A					,			
	AE									
	AF									
	AG									
	AH				4					
	AI									
	AJ									
	AK									
		FOREIGN	N PATENT I	OCUME	NTS					
11.		DOCUMENT NUMBER		DATE COUNTRY			TRANSLA	TION		
	AL									
	AM									
	AN									
	AO									
	AP									
	ОТ	ER ART (Includia	ng Author, Ti	tle, Date,	Pertinent Dates, Etc.					
	AU	Haley and Dietschy Editorial in Arch. Neurology Vol 57, Oct 2000 page 1409								
	AV	R. C. Petersen et al "Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence -based review)" Neurology 2001:56; 1122-1142								
	AW	Letters in Arch Neurol June 2001 : 1023 including letters by Lesser and Liebow Bollen, Gaw and Buckley								
EXAMINER	/Renee Clayto	DATE CONSIDERED 12/17/2008								
EXAMINER:		I if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if a conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE U-013913-4 10/099.858 INFORMATION DISCLOSURE APPLICANT STATEMENT BY APPLICANT **Bonnie M Davis** (Use several sheets if necessary) FILING DATE GROUP March 14, 2003 1617 U.S. PATENT DOCUMENTS FXAMINER REFERENCE DOCUMENT FILING DATE IF INITIALS DESIGNATION NUMBER DATE NAME APPROPRIATE AA AB AC AD AE ΑF AG AΗ ΑI AJ ΑK FOREIGN PATENT DOCUMENTS DOCUMENT. TRANSLATION NUMBER DATE COUNTRY YES NO ΑL AM AN AΩ AP OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.) Rockwood et al "Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in AAA Community-Dwelling Elderly People" Arch Neurol:59: Feb 2002 Yaffe et al "Serum ipoprotein Levels, Statin Use and Cognitive Function in Older Women" Arch AAB Neurol 59 March 2002 p 378 et seq Winblad et al "Effects of Statins on Cognitive Functions in Patients with Alzheimer's Disease in AAC Galantamine Clinical Trials Drugs Aging 200724(1) 57 - 61 12/17/2008 /Renee Claytor/ EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-			ATTY. DOCKET NO.		SERIAL NO.						
PATEN		AND TRADEMARK OFFICE		4 013913-4		10/099858					
INFORMATION DISCLOSURE				APPLICANT							
STATEMENT BY APPLICANT					BOWNIE M. DAVIS						
(Use several sheets if necessary)					FILING DATE			GROUP			
•				MARCH 14,7002 1			1617				
		U.S. I	PATENT DO	CUMEN	TS						
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER DAT		E	NAME	FILING DATE IF APPROPRIATE					
	AA										
	AB										
	AC										
	AD										
	AE										
	AF										
	AG										
	AH										
	AI										
	AJ				0						
	AK										
		FOREIG	N PATENT I	OCUMI	ENTS		12.4				
		DOCUMENT NUMBER	Ü.			11	TRANSL	ATION			
			DAT	E	E COUNTRY		YES	NO			
	AL										
	AM										
	AN										
	AO										
	AP						,				
	OTT	HER ART (Includi	ing Author, T	itle, Date	, Pertinent Dates, Etc	.)					
	AX	Letters in Arch Neurol July 2001 58: 1160 by Golomb									
	AY	Letters in Th Lancet March 17, 2002 by Bickenhager et al, by Cheung et al and by Blauw et al.						ct al.			
	AZ	MacMahon et al "Reliable Assessment of the effects of treatment on mortality and major mortality II: observational studied The Lancet 357:455 et seq.									
EXAMINER	/Renee Claytor	,		DATE	CONSIDERED 12/	17/2008					
EXAMINER:											